Form 4 Filing for IOVANCE BIOTHERAPEUTICS, INC.

This filing details a Form 4 submission by Ryan D. Maynard, a director at IOVANCE BIOTHERAPEUTICS, INC. (IOVA). On June 16, 2026, Maynard acquired 90,316 Deferred Restricted Stock Units (DRSUs) with a transaction price of $0.0 per share. These DRSUs are part of the Issuer's 2018 Equity Incentive Plan and represent a contingent right to one share of the Issuer's common stock. The vesting of these units is contingent upon Maynard continuing to provide services to the Issuer and will occur on the earlier of the first anniversary of the transaction date or the day before the Issuer's next annual shareholder meeting. Issuance of the common stock will be deferred until certain conditions are met, including post-employment periods, change in control, or a maximum of ten years from the transaction date. Following this transaction, Maynard holds 90,316 shares of common stock underlying the DRSUs.